問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Show-Chwan Memorial Hospital (在職)

Division of Hematology & Oncology

Chang Bing Show Chwan Memorial Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

吳敬炫
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳敬炫

List

10Cases

2023-05-10 - 2025-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2024-06-01 - 2027-07-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-10-01 - 2035-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2021-09-02 - 2026-09-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-04-30 - 2028-09-30

Phase III

Active
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

2025-03-01 - 2029-12-31

Others

Active
A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

  • Condition/Disease

    Refractory or Relapsed Multiple Myeloma

  • Test Drug

    皮下注射劑

Participate Sites
6Sites

Recruiting6Sites

2024-02-28 - 2030-03-31

Phase III

Active
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma

  • Condition/Disease

    Peripheral T-Cell Lymphoma

  • Test Drug

    injection

Participate Sites
6Sites

Recruiting6Sites

2023-05-10 - 2025-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2021-09-02 - 2026-05-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2028-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB